# A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension

> **NCT00779181** · PHASE2 · COMPLETED · sponsor: **Addrenex Pharmaceuticals, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** ADX415
- **DRUG:** ADX415
- **DRUG:** ADX415
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00779181
- **Lead sponsor:** Addrenex Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2008-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779181, "A Dose-Ranging Study of the Safety and Efficacy of ADX415 in the Treatment of Essential Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00779181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*